Monthly Archives: December 2011
Walvax Biotechnology calls off collaboration with GlaxoSmithKline
Walvax Biotechnology is reported to have ended negotiations for a collaboration with GlaxoSmithKline because China regulators decided against allowing GSK to import its measles-mumps-rubella vaccine. The vaccine was the centerpiece of a joint venture that Walvax and GSK announced two … Continue reading
Filed under alliances
Abbott terminates TRU-016 collaboration with Emergent BioSolutions
Emergent BioSolutions has announced receipt of a notice from Abbott that it is terminating its TRU-016 co-development and co-commercialization agreement. TRU-016, Emergent’s humanized anti-CD37 mono-specific protein therapeutic, recently began a Phase 2 clinical study for chronic lymphocytic leukemia and is … Continue reading
Filed under alliances
Immunomedics and UCB restructure autoimmune collaboration
Immunomedics and UCB have announced that they have amended their collaboration agreement for the exclusive worldwide rights to develop, market and sell epratuzumab for all autoimmune disease indications. According to the companies the restructuring provides UCB with the right to … Continue reading
Filed under alliances
Alexion Pharmaceuticals agrees to buy Enobia Pharma for £1.08 billion
Alexion Pharmaceuticals has announced that it has agreed to buy Enobia Pharma. Alexion will pay $610 million upon completion of the deal, and up to $470 million on achievement of various regulatory and sales milestones. Alexion said it will acquire … Continue reading
Filed under acquisitions
Acceleron Pharma raises $30 million
Acceleron Pharma has announced that it has raised a $30 million private financing. Celgene, one of Acceleron’s strategic partners, and all other existing investors participated in this financing. The proceeds will be used to expand and advance Acceleron’s clinical stage … Continue reading
Filed under funding
ViroPharma pays $7.5 million for an option to acquire Meritage Pharma for $69.9 million
ViroPharma has paid $7.5 million for an option to acquire Meritage Pharma for $69.9 million, plus milestones. ViroPharma also agreed to pay Meritage up to an additional $12.5 million in milestones before the option is exercised. ViroPharma can exercise the … Continue reading
Filed under acquisitions
Karo Bio signs $217 million autoimmune diseases collaboration with Pfizer
Karo Bio has announced that it has entered into a research collaboration agreement with Pfizer to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases. Under the agreement, Pfizer will provide full funding for the … Continue reading
Filed under alliances
Marina Biotech and Mirna Therapeutics sign $63 million collaboration
Marina Biotech and Mirna Therapeutics have announced that they have entered into a license agreement for the development and commercialization of microRNA-based therapeutics using Mirna’s microRNAs and Marina Biotech’s Smarticles liposomal delivery technology. Under the agreement Mirna will have full … Continue reading
Filed under alliances
Coronado Biosciences signs agreement with Dr. Falk Pharma and OvaMed to collaborate in the development of CNDO-201
Coronado Biosciences has announced an agreement with Dr. Falk Pharma and OvaMed to collaborate in the development of CNDO-201, or Trichuris suis ova (TSO), for Crohn’s disease. Under the agreement, Coronado, Falk and OvaMed have agreed to enter into a … Continue reading
Filed under alliances
Sanofi and Exelixis call off collaboration
Sanofi and Exelixis have announced that they have decided to end their cooperation on the discovery of inhibitors of Phosphoinositide 3-Kinase (PI3K) alpha and beta in cancer treatment. The agreement was signed in 2009 which was worth up to $1 … Continue reading
Filed under alliances
